// App-Quantinova.ai

TPS8586 : CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.

Researchers

Presenter

  • Dean Anthony Fennell

Principal Investigators

  • Emma Victoria Kirkpatrick

  • Kelly Cozens

  • Sarah Danson

  • Gerard G. Hanna

  • Jason Francis Lester

  • Joanne Lord

  • Mavis Nye

  • Christian H.H Ottensmeier

  • Peter Wojciech Szlosarek

  • Nicola L. Steele

  • Daniel T Barnes

  • Karan D Vadher

  • Tom Maishman

  • Stephanie J Hill

  • Gareth Griffiths

Medical Centers

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Sheffield Experimental Cancer Medicine Centre, Weston Park Hospital, Sheffield, United Kingdom

  • N Ireland Cancer Center, Belfast, United Kingdom

  • University Hospital of Wales, Heath Park, Cardiff/United Kingdom, Cardiff, United Kingdom

  • Wessex Institute Univerity of Southampton, Southampton, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

  • Barts Health NHS Trust, London, United Kingdom

  • Cancer Research UK, Southampton, United Kingdom

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Southampton Clinical Trials Unit,University of Southampton, Southampton, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • ISRCTN79814141

  • NCT03063450

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved